Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 8 Ovarian Neoplasms 5 Mesothelioma, Malignant 4 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Stomach Neoplasms 2 Neoplasms 2 Mesothelioma 2 Melanoma 2 Glioblastoma 2 Uveal Melanoma 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Phase IB 1 Non Hematologic Cancers 1 Neoplasms, Mesothelial 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mesonephric Gynecologic Cancer 1 Lymphoma 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × defactinib × Clear all

NCT06072781 2026-04-02

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡